Advertisement
Based on general market information, the proposed pricing for these newformulations will be approximately US$40.00 per unit, with 60% gross profitmargins. JPI plans to sell both products through existing distributionchannels within the Henan, Sichuan, Guizhou, Shanxi, Xinjiang, Gansu, Hunnan,Zhejiang, Fujian, Liaoning and Heilongjiang Provinces of China. Together theseregions have a combined population of more than 376 million people. Inaddition to China, AMDL believes both products will be good candidates forexport to the North American and European markets.
Advertisement
According to Gary Dreher, CEO of AMDL, "With the popularity of the Goodnakbrand in China, combined with JPI's ability to sell through pre-approveddistribution channels, we anticipate sales to exceed well beyond our initialannual sales forecast for Goodnak of $24 million. This is extremely positivenews for the market, Company and our shareholders."
Additional information on AMDL, Goodnak and the Company's otherpharmaceutical products is available at http://www.amdl.com.
About AMDL:
AMDL, Inc. is a global specialty pharmaceutical Company. The Company isheadquartered in Tustin, California with operations in Shenzhen, Jiangxi, andJilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDLis devoted to the research, development, manufacture, and marketing ofdiagnostic, pharmaceutical, nutritional supplement, and cosmetic productscurrently in China. The Company employs approximately 320 people in the U.S.and China.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer marketin the world: China. AMDL, through its subsidiaries, Jade currentlymanufactures large volume injection fluids, tablets and other relatedproducts, holding licenses for 133 products. It also manufactures 107 generic,over the counter and supplemental pharmaceutical products under certifiedChinese Good Manufacturing Practice (CGMP) standards.
Forward-Looking Statements
This news release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Such statements aresubject to certain risks and uncertainties, and actual circumstances, eventsor results may differ materially from those projected in such forward-lookingstatements. The Company cautions readers not to place undue reliance on anyforward-looking statements. The Company does not undertake, and specificallydisclaims any obligation, to update or revise such statements to reflect newcircumstances or unanticipated events as they occur.
Contact: Kristine Szarkowitz206.310.5323 [email protected]
SOURCE AMDL, Inc.